ixagliflozin

Ixagliflozin is an investigational small molecule drug classified as a dual sodium-glucose cotransporter 1 and 2 (SGLT-1/2) inhibitor. It is being explored for its potential in treating type 2 diabetes mellitus and atherosclerotic cardiovascular disease. By inhibiting both SGLT1 and SGLT2, ixagliflozin is expected to reduce glucose reabsorption in the kidneys and potentially delay intestinal glucose absorption, leading to lower blood glucose levels and offering cardiovascular and renal protective benefits. This mechanism of action is characteristic of the gliflozin class of drugs, which promote glucose excretion in the urine.